Business Context and Reporting Period
Company: Palatin Technologies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: Palatin is a biopharmaceutical company developing peptide and small molecule agonists targeting melanocortin and natriuretic peptide receptor systems. Key programs include bremelanotide for sexual dysfunction and PL-3994 for acute asthma and heart failure. The company maintains an exclusive collaboration with AstraZeneca for obesity and diabetes programs.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2011 | Nine Months Ended Mar 31, 2011 | Nine Months Ended Mar 31, 2010 |
|---|---|---|---|
| Total Revenues | $61,294 | $1,319,617 | $13,505,770 |
| Net Loss | $(3,805,878) | $(9,506,700) | $2,443,873 (Income) |
| Operating Expenses | $2,677,979 | $10,386,432 | $12,266,272 |
| Cash and Cash Equivalents (End of Period) | $22,032,649 (as of Mar 31, 2011) | ||
| Net Cash Used in Operating Activities | $(7,891,354) (Nine Months 2011) | ||
| Net Cash Provided by Financing Activities | $21,070,388 (Nine Months 2011) | ||
| Accumulated Deficit | $(218,680,878) (as of Mar 31, 2011) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues for the nine months ended March 31, 2011, dropped significantly to $1.32 million from $13.5 million in the prior year. This decrease is primarily due to the completion of the research collaboration portion of the AstraZeneca agreement in January 2010, which resulted in the recognition of substantial deferred up-front fees in the prior period. Current revenue consists mainly of reimbursement for development costs and grant revenue ($846,768).
- Net Loss vs. Income: The company reported a net loss of $9.5 million for the nine months ended March 31, 2011, compared to a net income of $2.4 million in the same period of 2010. The loss was driven by lower revenues and a non-operating expense of $1.26 million related to the increase in fair value of warrant liabilities.
- Capital Raise: On March 1, 2011, the company completed a public offering of 23 million units (common stock and warrants) at $1.00 per unit, generating net proceeds of approximately $21.1 million. This significantly increased cash balances from $5.4 million to $22.0 million.
- Expense Reduction: Operating expenses decreased year-over-year due to a strategic decision in September 2010 to reduce staffing levels and focus resources on specific clinical trials (bremelanotide and PL-3994).
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing capital resources ($22.0 million) are sufficient to fund planned operations, specifically clinical trials for bremelanotide for female sexual dysfunction, through at least calendar year 2012.
- Strategic Focus: The company has suspended R&D on new product candidates and is focusing on bremelanotide (FSD and ED) and PL-3994 (asthma, heart failure). A Phase 2 trial for bremelanotide in women is scheduled to start in Q2 2011.
- Future Funding Needs: Current funds are likely insufficient to complete all required clinical trials for product approval. The company intends to seek additional capital through public/private financings or collaborative arrangements. Failure to secure funding could require curtailing operations.
- Warrant Liability: A portion of Series B Warrants issued in March 2011 was classified as a liability ($6.37 million) due to insufficient authorized shares. This liability was reclassified to equity following stockholder approval to increase authorized shares on May 11, 2011.
- Listing Status: The company is under review for compliance with NYSE Amex continued listing standards regarding stockholders' equity and losses. Failure to comply by May 26, 2011, could result in delisting.
Key Facts for Investor Verification
- Cash Runway: Verify if the $22.0 million cash balance is sufficient to sustain operations through 2012 given the high burn rate of clinical trials.
- Warrant Liability Reclassification: Confirm the impact of the May 11, 2011 stockholder vote on the balance sheet, specifically the removal of the $6.37 million warrant liability and its reclassification to equity.
- Revenue Concentration: Note that 100% of license and contract revenues for the period were derived from the AstraZeneca collaboration, which has shifted from up-front fee recognition to cost reimbursement.
- Listing Compliance: Monitor the company's status regarding NYSE Amex listing requirements, specifically the $6 million stockholders' equity threshold and loss limitations.
- Dilution Risk: Assess the potential dilution from 23 million shares issued in the March 2011 offering plus 23 million shares underlying warrants (Series A and B) and existing options.